Evidence map›Paper›PMID 29197426›Full record

ArticleParasites & vectors2017

Phenotypic and genotypic monitoring of Schistosoma mansoni in Tanzanian schoolchildren five years into a preventative chemotherapy national control programme.

Charlotte M Gower, Florian Gehre, Sara R Marques, Poppy H L Lamberton, Nicholas J Lwambo, Joanne P Webster

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 3 countries.

Charlotte M GowerCentre for Endemic, Emerging and Exotic Diseases, The Royal Veterinary College, University of London, London, AL9 7TA, UK. c.gower@imperial.ac.uk.
Florian GehreDepartment of Infectious Disease Epidemiology, Imperial College, Faculty of Medicine, W2 1PG, London, UK.
Sara R MarquesDepartment of Life Sciences, Imperial College, Faculty of Medicine, London, UK.
Poppy H L LambertonDepartment of Infectious Disease Epidemiology, Imperial College, Faculty of Medicine, W2 1PG, London, UK.
Nicholas J LwamboMwanza Research Centre, National Institute for Medical Research, Mwanza, Tanzania.
Joanne P WebsterCentre for Endemic, Emerging and Exotic Diseases, The Royal Veterinary College, University of London, London, AL9 7TA, UK.
Imperial College London · GBInstituut voor Tropische Geneeskunde · BENational Institute for Medical Research · TZRoyal Veterinary College · GBUniversity of London · GBWellcome Centre for Molecular Parasitology · GB

Funding

Royal Society (GB) DHF
6 · The paper itself

Abstract

backgroundSchistosoma mansoni is a parasite of profound medical importance. Current control focusses on mass praziquantel (PZQ) treatment of populations in endemic areas, termed Preventative Chemotherapy (PC). Large-scale PC programmes exert prolonged selection pressures on parasites with the potential for, direct and/or indirect, emergence of drug resistance. Molecular methods can help monitor genetic changes of schistosome populations over time and in response to drug treatment, as well as estimate adult worm burdens through parentage analysis. Furthermore, methods such as in vitro drug sensitivity assays help phenotype in vivo parasite genotypic drug efficacy.

methodsWe conducted combined in vitro PZQ efficacy testing with population genetic analyses of S. mansoni collected from children from two schools in 2010, five years after the introduction of a National Control Programme. Children at one school had received four annual PZQ treatments and the other school had received two mass treatments in total. We compared genetic differentiation, indices of genetic diversity, and estimated adult worm burden from parasites collected in 2010 with samples collected in 2005 (before the control programme began) and in 2006 (six months after the first PZQ treatment). Using 2010 larval samples, we also compared the genetic similarity of those with high and low in vitro sensitivity to PZQ.

resultsWe demonstrated that there were individual parasites with reduced PZQ susceptibility in the 2010 collections, as evidenced by our in vitro larval behavioural phenotypic assay. There was no evidence, however, that miracidia showing phenotypically reduced susceptibility clustered together genetically. Molecular analysis also demonstrated a significant reduction of adult worm load over time, despite little evidence of reduction in parasite infection intensity, as measured by egg output. Genetic diversity of infections did not reduce over time, despite changes in the genetic composition of the parasite populations.

conclusionsGenotypic and phenotypic monitoring did not indicate a selective sweep, as may be expected if PZQ treatment was selecting a small number of related "resistant" parasites, but there was evidence of genetic changes at the population level over time. Genetic data were used to estimate adult worm burdens, which unlike parasite infection intensity, showed reductions over time, suggesting the relaxation of negative density-dependent constraints on parasite fecundity with PZQ treatment. We thereby demonstrated that density-dependence in schistosome populations may complicate evaluation and monitoring of control programmes.

Indexed as

Drug ResistanceGenetic VariationAnimalsAnthelminticsChildGenotypeHumansNational Health ProgramsPraziquantelSchistosoma mansoniSchistosomiasis mansoniTanzaniaAnthelminticsPraziquantelDensity-dependenceDrug resistanceNeglected tropical diseasesPopulation geneticsPraziquantelSchistosomiasis

Identifiers

PMID29197426
PMCPMC5712074
OpenAlexW2772853575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.